David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
426
DELISTED
CATALENT, INC.
CTLT
| $41.5M | 0.05% |
1,021,873
-1,347,357
| -57% | -$52.6M |
|
427
CALL
Broadcom
AVGO
$1.72T
| $40.8M | 0.05% |
1,356,000
-962,000
| -42% | -$26.1M |
|
428
Nektar Therapeutics
NKTR
$2.52B
| $40.8M | 0.05% |
80,881
+28,239
| +54% | +$16.7M |
|
429
Stride
LRN
$3.55B
| $40.5M | 0.05% |
1,186,032
+120,611
| +11% | +$3.68M |
|
430
CALL
General Motors
GM
$76.1B
| $40.4M | 0.05% |
1,089,900
-1,745,000
| -62% | -$66.3M |
|
|
WCC
431
WESCO International
WCC
$16.4B
| $40.4M | 0.05% |
761,698
-12,921
| -2% | -$683K |
|
432
CALL
Snap
SNAP
$9.22B
| $40.3M | 0.05% |
3,655,000
+750,000
| +26% | +$6.38M |
|
433
ASML
ASML
$670B
| $40.2M | 0.05% |
213,970
-478,862
| -69% | -$84.8M |
|
434
State Street
STT
$52.2B
| $40.2M | 0.05% |
611,171
+24,858
| +4% | +$1.72M |
|
435
Willis Towers Watson
WTW
$32.3B
| $40.2M | 0.05% |
228,676
-528,499
| -70% | -$87.7M |
|
|
P
436
Everpure Inc
P
$33.7B
| $40.1M | 0.05% |
1,841,668
+1,152,755
| +167% | +$21.9M |
|
437
Duke Energy
DUK
$95B
| $40M | 0.05% |
444,430
+429,131
| +2,805% | +$37.8M |
|
438
Autohome
ATHM
$2.51B
| $40M | 0.05% |
380,208
-316,592
| -45% | -$26.1M |
|
|
GRUB
439
DELISTED
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
| $39.7M | 0.05% |
285,858
-697,418
| -71% | -$108M |
|
440
Norfolk Southern
NSC
$78.8B
| $39.4M | 0.05% |
210,617
+137,631
| +189% | +$23.8M |
|
441
BlackBerry
BB
$4.51B
| $38.9M | 0.05% |
3,856,326
+1,436,102
| +59% | +$12.1M |
|
|
PARA
442
DELISTED
Paramount Global Class B
PARA
| $38.7M | 0.05% |
813,802
+235,226
| +41% | +$11.5M |
|
443
Acadia Pharmaceuticals
ACAD
$5.1B
| $38.7M | 0.05% |
1,439,981
+1,290,639
| +864% | +$30.1M |
|
444
PUT
Blackrock
BLK
$180B
| $38.6M | 0.05% |
90,300
+14,200
| +19% | +$5.96M |
|
445
Insperity
NSP
$2B
| $38.6M | 0.05% |
311,835
+56,967
| +22% | +$6.5M |
|
446
Synchrony
SYF
$25.9B
| $38.5M | 0.05% |
1,207,215
-1,652,140
| -58% | -$49.7M |
|
|
VISN
447
Vistance Networks Inc
VISN
$2.54B
| $38.4M | 0.05% |
1,768,358
-104,374
| -6% | -$2.19M |
|
448
Enbridge
ENB
$110B
| $38.3M | 0.05% |
1,057,779
-1,286,130
| -55% | -$46.3M |
|
449
News Corp Class A
NWSA
$16.5B
| $38.3M | 0.05% |
3,077,800
-61,664
| -2% | -$776K |
|
450
Texas Capital Bancshares
TCBI
$4.25B
| $38.2M | 0.05% |
699,767
+113,778
| +19% | +$6.59M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.